Sutro Biopharma, Inc.
STROHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeSutro Biopharma, Inc. operates as an oncology company. With a market capitalization of $154.7M, it sits in micro-cap territory. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+.
Market Cap
$154.7M
Beta
1.50
P/E (TTM)
—
P/E (Fwd)
-1.50
EPS (TTM)
$-17.28
EPS (Fwd)
$-6.21
ROE
—
ROA
-36.1%
Cash
$164.3M
Total Debt
$10.8M
Free CF
-$100.8M
52W Change
-19.6%
Annual Financials
Cash vs Debt
Where STRO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, STRO finished 55.23% below its 150-day moving average ($25.15) and 51.28% below its 200-day moving average ($23.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is STRO overbought or oversold?
At the October 20, 2026 close, STRO's RSI(14) was 23.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $164.3M in cash comfortably exceeding the $10.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$100.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $67.8M (2022) to $102.5M (2025), reflecting a 51% increase over the period.
With cash comfortably exceeding debt, STRO has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing STRO.